NCT01697579View on ClinicalTrials.gov

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

PHASE2CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 13, 2012

Primary Completion Date

November 21, 2016

Study Completion Date

November 21, 2016

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Fosaprepitant

Administered intravenously (IV) as a single dose

DRUG

Fosaprepitant Placebo

Administered IV as a single dose

DRUG

Ondansetron

Administered IV according to local labeling and/or local standard of care

DRUG

5-hydroxytryptamine 3 antagonist

Administered IV according to local labeling and/or local standard of care

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01697579 - Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) | Biotech Hunter | Biotech Hunter